• More Severe Disease in MG Patients with LRP4 and Agrin Autoantibodies, Study Finds
  • 3P Biopharmaceuticals and Toleranzia Advance Partnership to Develop TOL2  for MG
  • Immunovant Prepares to Launch Phase 3 Trial of IMVT-1401 in MG Patients
  • Rituximab Effective for People With Refractory MG, Study Finds
  • Mitochondria Defects in Immune Cells May Cause MG, Study Says
  • Alexion Charitable Foundation Giving $1.1M to Assist Rare Disease Community During Pandemic
  • Rituximab More Beneficial if Given to gMG Patients Early, Study Finds
  • Nipocalimab Does Well in Top-line Results of Phase 2 Vivacity-MG Trial
  • Early Success After Thymectomy Predicts Long-term Benefits for MG Patients, Study Finds
  • CAAR T-cell Therapy Shows Early Potential for MuSK-linked MG
  • Coalition Will Address Racial Disparities in Rare Disease Communities
  • MG Illuminate Event and MG United, by Argenx, Shine Light on Rare Disease